Asset Details
Do you wish to reserve the book?
IA First-Class Degrader Candidate Targeting Both/I KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
IA First-Class Degrader Candidate Targeting Both/I KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination
Do you wish to request the book?
IA First-Class Degrader Candidate Targeting Both/I KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
IA First-Class Degrader Candidate Targeting Both/I KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination
2023
Overview
“Undruggable” targets such as KRAS are particularly challenging in the development of drugs. We devised a novel chemical knockdown strategy, CANDDY (Chemical knockdown with Affinity aNd Degradation DYnamics) technology, which promotes protein degradation using small molecules (CANDDY molecules) that are conjugated to a degradation tag (CANDDY tag) modified from proteasome inhibitors. We demonstrated that CANDDY tags allowed for direct proteasomal target degradation independent of ubiquitination. We synthesized a KRAS-degrading CANDDY molecule, TUS-007, which induced degradation in KRAS mutants (G12D and G12V) and wild-type KRAS. We confirmed the tumor suppression effect of TUS-007 in subcutaneous xenograft models of human colon cells (KRAS G12V) with intraperitoneal administrations and in orthotopic xenograft models of human pancreatic cells (KRAS G12D) with oral administrations. Thus, CANDDY technology has the potential to therapeutically target previously undruggable proteins, providing a simpler and more practical drug targeting approach and avoiding the difficulties in matchmaking between the E3 enzyme and the target.
Publisher
MDPI AG
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.